Pharmacokinetic (PK) guided optimization of 5-fluorouracil (5-FU) dosing in the treatment of patients with colorectal cancer (CRC)

被引：0
|
作者：
Goal, Gaurav
Chu, Edward
Sun, Min
Meisner, Dennis James
Lee, James J.
机构：
[1] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA
[2] UPMC Canc Ctr, Pittsburgh, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14561
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Therapeutic drug monitoring of 5-fluorouracil (5-FU) in the treatment of patients with colorectal cancer (CRC)
    Goel, Gaurav
    Sehgal, Rajesh
    Meisner, Dennis James
    Sun, Min
    Pasricha, Gurleen
    Chu, Edward
    Lee, James J.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [2] Pharmacokinetic (PK)-guided optimization of 5-fluorouracil (5FU) exposure in colorectal cancer (CRC) patients: USbased clinical practices experience.
    Braiteh, Fadi S.
    Salamone, Salvatore J.
    Li, Yunying
    Courtney, Jodi B.
    Duda, Michael
    Diamond, Steve
    Miller, Michael Craig
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [3] NONLINEAR PHARMACOKINETIC CHARACTERISTICS OF 5-FLUOROURACIL (5-FU) IN COLORECTAL-CANCER PATIENTS
    SCHAAF, LJ
    DOBBS, BR
    EDWARDS, IR
    PERRIER, DG
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1987, 32 (04) : 411 - 418
  • [4] A pilot approach of pharmacokinetically guided 5-fluorouracil (5-FU) dosing for personalized gastric cancer treatment.
    Alvarez, Eduardo Castanon
    Aldaz, Azucena
    Eggaaes, Amaia
    Martin, Patricia
    Fusco, Juan Pablo
    Zubiri, Leire
    Ceniceros, Lucia
    Chopitea, Ana
    Hernandez-Lizoain, Jose Luis
    Rodriguez, Javier
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [5] Cardiac outcomes of raltitrexed in the treatment of colorectal cancer patients with 5-fluorouracil (5-FU) cardiotoxicity
    Firouzbakht, Aryan
    Renouf, Daniel John
    Chen, Leo
    Cheung, Winson Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [6] A prospective, multi-center study of individualized, pharmacokinetically (PK)-guided dosing of 5-fluorouracil (5-FU) in metastatic colorectal cancer (mCRC) patients treated with weekly or biweekly 5-FU/oxaliplatin containing regimens
    Kunzmann, Volker
    Link, Karin
    Miller, Michael Craig
    Holdenrieder, Stefan
    Bertsch, Thomas
    Mueller, Lothar
    Ko, Yon-Dschun
    Stoetzer, Oliver J.
    Suttmann, Ingo
    Braess, Jan
    Jaehde, Ulrich
    Roessler, Max
    Moritz, Berta
    Kraff, Stefanie
    Fritsch, Achim
    Salamone, Salvatore J.
    Wilhelm, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [7] Methotrexate (MTX) and 5-fluorouracil (5-FU) in advanced colorectal cancer patients previously treated with adjuvant 5-FU
    Pronzato, P
    Vaira, F
    Viganni, A
    Losardo, P
    Bertelli, G
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 760 - 760
  • [8] 5-FLUOROURACIL (5-FU) COMBINED WITH LEUCOVORIN (LV) IN PATIENTS WITH ADVANCED 5-FU RESISTANT COLORECTAL-CANCER
    VANGROENINGEN, CJ
    PETERS, GJ
    PINEDO, HM
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1988, 29 : 202 - 202
  • [9] Pharmacokinetic (PK) interaction between 5-fluorouracil (5-FU) and oxaliplatin (L-OHP).
    Papamichael, D
    Joel, SP
    Seymour, M
    Richards, F
    Bowerbank, M
    Slevin, ML
    BRITISH JOURNAL OF CANCER, 1998, 78 : 12 - 12
  • [10] Doxifluridine in colorectal cancer patients resistant to 5-fluorouracil (5-FU) containing regimens
    Bajetta, E
    DiBartolomeo, M
    Somma, L
    DelVecchio, M
    Artale, S
    Zunino, F
    Bignami, P
    Magnani, E
    Buzzoni, R
    EUROPEAN JOURNAL OF CANCER, 1997, 33 (04) : 687 - 690
12345